BIM
BLPH

BlackRock Investment Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

BlackRock Investment Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-56
Closed -$2K – 4175
2016
Q1 		$2K Hold
56
– – ﹤0.01% 3993
2015
Q4 		$3K Hold
56
– – ﹤0.01% 3977
2015
Q3 		$4K Hold
56
– – ﹤0.01% 4000
2015
Q2 		$7K Hold
56
– – ﹤0.01% 3873
2015
Q1 		$8K Buy
+56
New +$8.72K ﹤0.01% 3750

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GA
Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

BlackRock Investment Management's BLPH Position: Q2 2016 in Review

BlackRock Investment Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2016, closing a stake of 56 shares — an estimated $2K sold.

BlackRock Investment Management first reported a position in BLPH in Q1 2015 and held it in 5 quarters. The position peaked at $8K in Q1 2015. 17 funds tracked by Wall St. Rank hold BLPH as of Q2 2016.

  • BlackRock Investment Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 56 Bellerophon Therapeutics, Inc. shares in Q2 2016, an estimated $2K.
  • BlackRock Investment Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 5 quarters.
  • BlackRock Investment Management's Bellerophon Therapeutics, Inc. position peaked at $8K in Q1 2015.
  • 17 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.